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model parameters resulted in incremental cost effectiveness
values ranging from $19,612–$56,120 per additional life-year
gained. CONCLUSIONS: The increase in survival time associ-
ated with adding goserelin to a conventional radiation treatment
strategy comes with additional costs. However, the addition of
goserelin to radiation is cost-effective based on the often cited
$50,000/per life-year gained incremental cost-effectiveness
threshold.
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OBJECTIVES: Results from the ATAC trial indicated that anas-
trozole was superior to tamoxifen for disease free survival (DFS)
in the adjuvant treatment of postmenopausal women with
hormone receptor-positive (HR+) early breast cancer, at median
follow up of 33 months (Lancet 2002;359:2131–39) and 47
months (Cancer 2003;98:1802–10). We calculated the incre-
mental cost-effectiveness ratio (ICER) per life year gained (LYG)
for anastrozole compared to tamoxifen from the US health care
perspective, using the recent 47 month data. METHODS: A
probabilistic Markov model was developed using the updated
ATAC data to project outcomes for both anastrozole and tamox-
ifen to 25 years by extrapolating pooled Kaplan-Meier curves
using parametric statistical methods. It was assumed that recur-
rence rates after the maximum 5-year treatment period would be
equivalent in the anastrozole and tamoxifen groups (a conserv-
ative approach). General mortality data were from US Census
2000. Resource utilization data were obtained from published
literature and structured interviews with 9 US oncologists. Drug
costs were based on average wholesale price and the generic 
cost of tamoxifen. Other unit costs (2002 US$) from standard
national sources and literature were used. Costs and beneﬁts
were discounted at 3%. Sensitivity analyses were conducted.
RESULTS: In a cohort of 1000 patients modeled over 25 years,
anastrozole was estimated to lead to 145 discounted LYG at 
an additional cost of $3.6 million. The discounted ICER of 
anastrozole compared with tamoxifen was estimated to be
$25,169/LYG (95% CI $5925–$48,593). Acceptability curves
showed that the estimated cost/LYG at 25 years was <$50,000
with a probability >90%. The result compared favorably with
commonly accepted thresholds for cost-effectiveness and was
robust to all parameters in sensitivity analyses, including adverse
events. CONCLUSIONS: Based on these ﬁndings, anastrozole
should be a cost-effective alternative to tamoxifen for the adju-
vant treatment of postmenopausal women with HR+ early breast
cancer.
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OBJECTIVE: The use of taxane therapy (paclitaxel and doc-
etaxel) is common for the treatment of metastatic breast cancer
(MBC) and is associated with the development of severe toxici-
ties. These toxicities are often dose limiting and can reduce the
effectiveness of taxane therapy. There are limited data on the eco-
nomic consequences of managing toxicities. The objective of this
analysis is to quantify the direct medical costs of managing
taxane-related toxicities in patients with MBC. METHODS: An
economic model was created to estimate the direct medical costs
associated with the management of taxane-related toxicities.
Model inputs were obtained from published literature, clinical
trial data, and expert opinion. Primary model inputs included
incidence of toxicities, costs of managing toxicities, and the fre-
quency of taxane use in patients with MBC. Costs were inﬂated
to 2003 dollars using the Medical Consumer Price Index.
RESULTS: The estimated costs of managing taxane-related 
toxicities were $7251 per patient treated with paclitaxel and
$17,580 per patient treated with docetaxel. The higher cost for
patients treated with docetaxel was primarily driven by a higher
incidence of adverse events. Disease prevalence estimates and
treatment patterns indicated 55,783 patients with incident cases
of MBC would receive taxane therapy annually in the U.S., with
38% receiving paclitaxel and 62% receiving docetaxel. The
annual direct medical costs associated with managing taxane-
related toxicities in the U.S. are approximately $762.4 million.
CONCLUSIONS: Direct medical costs associated with the man-
agement of toxicities are considerable although disease progres-
sion costs related to the dose-limiting effects of toxicities were
not modeled. Reduction in the incidence and/or severity of
taxane-related toxicities could result in substantially lower
medical expenditures for health care payers.
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OBJECTIVES: Prostate cancer is the most common non-skin
cancer in men in the United States. In 2003, the American Cancer
Society estimated that 220,900 men will be diagnosed with
prostate cancer and 28,900 men would die. Hospitalization 
data provided an opportunity to estimate the economic burden
of prostate cancer and examine what factors were associated
with spending. The objectives are to describe the demographics
of the hospitalized prostate cancer patients, and to explore
factors contributing to spending on prostate cancer hospital-
ization. METHODS: Nationwide Inpatient Sample 1999 data
was used. ICD-9 code for prostate cancer (185) was used to
extract patients with prostate cancer as the primary diagnosis.
2032 men were included in the study. Descriptive statistics on
patient demographics was produced and multivariate regression
was conducted to examine factors associated with hospital
expenditure on prostate cancer. The dependent variable was total
charges. The independent variables included age in years at
admission, died during hospitalization, number of diagnoses 
and number of procedures on this record, location of hospital,
teaching status of hospital, length of stay, admission source,
expected primary and secondary payer, region of hospital, 
and income. SPSS 10.0 was used for all statistical analyses.
RESULTS: The average total charge was $13,242.50. Higher
total charges were associated with the following variables:
younger age, Hispanic origin, admitted from another hospital,
alive at discharge, more procedures performed during hospital-
ization, increased length of stay, and urban, western and non-
teaching hospital, and lower incomes. CONCLUSIONS: This
study provided insight on hospital expenditures for prostate
cancer patients and can be used to develop strategies to reduce
unnecessary total charges.
